UBS maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but reduced its price target to $137 from $154, ...
Copyright 2025 The Associated Press. All Rights Reserved. North Carolina guard Reniya Kelly (10) and SMU guard Nya Robertson (3) try to win a loose ball during the ...
Robert Vilahamn reported that Charlotte Grant will be back and available for selection for Sunday’s Barclays Women’s Super League clash with West Ham United. The defender missed last weekend’s defeat ...
Both 40 mg and 80 mg doses of INGREZZA showed substantial improvements in AIMS total scores, with mean baseline scores declining markedly by Week 48. The remission rates were consistent irrespective ...
(RTTNews) - Neurocrine Biosciences Inc. (NBIX), Thursday unveiled new data at the 2025 Psychiatry Update Conference in Chicago, highlighting the long-term efficacy of INGREZZA or valbenazine in ...
Ingrezza is expected to bring in approximately $6.2bn for the company by the end of the decade. Following closely behind is Teva Pharmaceutical’s Austedo (deutetrabenazine), which earned $1.6bn in ...
"These findings further establish INGREZZA as a highly effective long-term treatment option for individuals living with tardive dyskinesia, regardless of their underlying psychiatric condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback